Clinical Trial

LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG

Study acronym: LIBERTYLUNG
Recruiting
View on ClinicalTrials.gov →
Summary
Patient with histologically proven NSCLC in a metastatic stage, treatment naïve and eligible for first-line treatment with immune checkpoint inhibitor. Combination with chemotherapy is possible. Presence of a mutation after NGS analysis is required for ctDNA follow-up.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2021-03-05; most recent amendment 2025-09-17.
Status change: Not Yet Recruiting → Recruiting 2021-07-12
Trial Details
NCT Number NCT04790682
Lead Sponsor Institut Curie
Conditions Metastatic Lung Cancer
Enrollment 300 participants
Start Date 2021-05-22
Primary Completion 2029-06-03 (estimated)
Study Completion 2030-06-03 (estimated)
Updated on ClinicalTrials.gov 2025-09-18